Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit

J Clin Lipidol. 2015 Sep-Oct;9(5):703-8. doi: 10.1016/j.jacl.2015.07.005. Epub 2015 Jul 18.

Abstract

Background: Familial hypercholesterolemia (FH) is the most common dominantly inherited cause of premature coronary artery disease (CAD). However, the diagnosis of FH in patients who have premature CAD in hospital settings is under-recognized, this also represents a missed opportunity for screening their close family members and implementing primary prevention.

Objective: To investigate the point prevalence of FH in a coronary care unit (CCU) among patients with early-onset CAD.

Methods: The prevalence of FH, based on modified phenotypic Dutch Lipid Clinic Network Criteria, and the spectrum of associated CAD risk factors, were investigated in a CCU setting. Data were collected on 175 coronary care patients with onset of CAD at age <60 years.

Results: The prevalence of probable/definite FH was 14.3% (95% confidence interval, 9.0%-19.5%); 46.3% of the patients gave a family history of premature CAD and 20.6% had an untreated low-density lipoprotein cholesterol >5.0 mmol/L. Diabetes, hypertension, obesity, and smoking were common and equally prevalent in patients with and without FH.

Conclusions: FH is relatively frequent among patients with a history of early-onset CAD in the CCU. Every effort should be made to detect FH in these patients and to initiate cascade testing of available family members to prevent the development of CAD in those who may be unaware that they also have the condition.

Keywords: Coronary care unit; Familial hypercholesterolemia; Prevalence; Screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coronary Artery Disease / complications*
  • Coronary Artery Disease / therapy*
  • Coronary Care Units*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II / complications*
  • Hyperlipoproteinemia Type II / drug therapy
  • Male
  • Middle Aged
  • Patient Admission*
  • Prevalence
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors